Listen now (21 mins) | January 9, 2015 - Read the full Forbes article and watch the interview here: http://onforb.es/1DDwd2I. Subscribe to this podcast on iTunes by clicking here: http://bit.ly/ymotwitunes or on Stitcher by clicking here: http://bit.ly/ymotwstitcher. Jill O’Donnell-Tormey is the CEO and director of scientific affairs for the Cancer Research Institute, which focuses its research budget on promising cancer immunotherapy research. In recent years, new drugs like Yervoy, Opdivo and Keytruda have some people talking about “curing” cancer–and it isn’t just the patients. “As a scientist, I have been reluctant in the past to use the word “cure” when it comes to cancer, but the durable remissions we are now seeing in some previously untreatable patients gives me and many others great hope that we will, in fact, one day eliminate cancer deaths and effectively cure this disease,” O’Donnell-Tormey says. “The immune system plays an important role in cancer development and control, and we’re learning through scientific research how the two are related, with the end result being new ways to treat and in some cases prevent cancer with drugs that augment and direct the body’s inherent defenses,” she concludes. Please consider whether a friend or colleague might benefit from this piece and, if so, share it.